Clinical effect study of sacubitril/valsartan combined with dapagliflozin in the treatment of heart failure with reduced ejection fraction
沙库巴曲缬沙坦联合达格列净治疗射血分数降低性心衰的临床效果研究

摘要

目的 分析沙库巴曲缬沙坦联合达格列净用于射血分数降低性心力衰竭中的使用价值。方法 选取我院收治的射血分数降低性心衰患者126例，研究时间2024年2月至2025年3月。选取63例单独使用沙库巴曲缬沙坦治疗（对照组），另63例联合达格列净治疗（观察组）。观察单一治疗和联合治疗的疗效，对比两种疗法在左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）、左心室射血分数（left ventricular ejection fraction, LVEF）等心功能水平和生活质量的区别，记录不同疗法对其不良反应的影响。结果 观察组总有效率98.41%（62/63），对照组有效率85.71%（54/63），差异明显（P<0.05）。治疗前，两组患者心功能水平、生活质量评分相比（P>0.05）；治疗后，观察组LVESD、LVEF及生活质量评分均明显上升，且其LVEDD指标水平低于对照组，组间心功能、生活质量比较差异显著（P<0.05）。观察组不良反应发生率明显低于对照组（4.76%vs12.70%），差异显著（P<0.05）。结论 对射血分数降低性心力衰竭患者而言，实施沙库巴曲缬沙坦联合达格列净在疗效、心功能改善、减轻不良反应等方面占据明显优势，建议临床推广与使用。

Abstract

Objective To analyze the value of sacubitril/valsartan combined with dapagliflozin in the treatment of heart failure with reduced ejection fraction.
Methods A total of 126 patients with heart failure due to reduced ejection fraction admitted to our hospital were selected. The research period was from February 2024 to March 2025. Sixty-three cases were selected for treatment with sacubitril/valsartan alone (control group), and another 63 cases were treated with dapagliflozin in combination (observation group). Observe the therapeutic effects of single treatment and combined treatment, and compare the differences between the two therapies in cardiac function levels such as left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), and quality of life. Record the impact of different therapies on their adverse reactions.
Results The total effective rate was 98.41% (62/63) in the observation group and 85.71% (54/63) in the control group, with a significant difference (P<0.05). Before treatment, there was no significant difference in cardiac function levels and quality of life scores between the two groups before treatment (P>0.05).; After treatment, the LVESD, LVEF and quality of life scores in the observation group all increased significantly, and the LVEDD index level was lower than that in the control group. There were significant differences in cardiac function and quality of life between the groups (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (4.76%vs12.70%), and the difference was significant (P<0.05).
Conclusion   For patients with heart failure due to reduced ejection fraction, the implementation of sacubitril/valsartan combined with dapagliflozin has obvious advantages in terms of therapeutic effect, improvement of cardiac function, and reduction of adverse reactions. It is recommended for clinical promotion and application.